GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Centessa Pharmaceuticals
Centessa Pharmaceuticals is a unique biotech company with a decentralized R&D model. Its stock price reflects the successes and failures of its numerous subsidiaries, each focused on a single asset. The chart represents a portfolio bet on pharmaceutical innovation.
Share prices of companies in the market segment - Pharma neurology
Centessa is a unique biotech company with a decentralized R&D model. We classify it as a pharmaceutical company (neurology), and the chart below reflects general trends and investor sentiment in this biotech sector.
Broad Market Index - GURU.Markets
Centessa Pharmaceuticals is a biopharmaceutical company with a unique model that develops a portfolio of promising drug candidates from various companies. Its strategy makes it a prominent player in the GURU.Markets index. The chart below represents the entire market. Find out how Centessa compares to it.
Change in the price of a company, segment, and market as a whole per day
CNTA - Daily change in the company's share price Centessa Pharmaceuticals
For Centessa Pharmaceuticals, a biopharmaceutical company, change_co is a measure of the sector's inherently high volatility. Each daily change reflects sensitivity to news about clinical trials of its drugs. This metric isn't just noise, but a critical component of the models on System.GURU.Markets that assess risk in innovative medicine.
Daily change in the price of a set of shares in a market segment - Pharma neurology
Centessa Pharmaceuticals plc is a biotech company. This chart highlights the sector's extreme volatility. Comparison with CNTA's performance, with its unique drug development model, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Centessa Pharmaceuticals is a biopharmaceutical company with a unique development model aimed at mitigating risks in the volatile biotech sector. The chart below reflects average fluctuations in the industry, providing context for evaluating Centessa shares.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Centessa Pharmaceuticals
Centessa is a unique biotech company with a diversified pipeline. Its annual performance has been extremely volatile, reflecting both successes and failures in clinical trials, typical of this high-risk strategy.
Annual dynamics of market capitalization of the market segment - Pharma neurology
Centessa Pharmaceuticals plc is a biotech company with a unique model that manages a portfolio of several drug development subsidiaries. This structure is designed to diversify risks. The chart below shows how the market views this innovative approach to drug development and its clinical successes.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Centessa Pharmaceuticals is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the key events are data releases, not macroeconomic statistics.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Centessa Pharmaceuticals
Centessa is a unique biopharmaceutical company operating under a hub-and-spoke model with a portfolio of independent research programs. Sharp monthly fluctuations on the chart reflect news about clinical trials in any of these numerous programs.
Monthly dynamics of market capitalization of the market segment - Pharma neurology
Centessa Pharmaceuticals is a biopharmaceutical company with a unique model, managing a portfolio of subsidiaries, each focused on developing a single promising drug. The dynamics of its sector, shown in the chart, reflect the risks of R&D. Against this backdrop, one can assess how Centessa's decentralized approach to drug development impacts its chances of success.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Centessa Pharmaceuticals is a biotech company with a unique asset-centric model, managing a portfolio of subsidiaries, each focused on a single program. The chart below shows how risk diversification within the portfolio impacted stock volatility compared to biotechs with a single key drug.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Centessa Pharmaceuticals
For biopharmaceutical company Centessa, weekly stock performance is the pulse of its clinical developments. The price reacts sharply to the publication of trial data, regulatory decisions, and news about progress in developing new drugs. The chart below clearly illustrates how short-term scientific events shape value in innovative pharmaceuticals.
Weekly dynamics of market capitalization of the market segment - Pharma neurology
How does Centessa Pharmaceuticals' performance compare to the broader biotech sector? This chart compares the company's weekly stock price movements, driven by news about its broad pipeline, with the overall trend. This helps us understand whether the stock's movements reflect general investor sentiment or unique events within the company.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Centessa Pharmaceuticals uses an innovative model for drug development, aiming to improve research efficiency. This chart compares its weekly performance to the market. It shows how its stock, like other biotechs, is unaffected by the market and driven by clinical trial news.
Market capitalization of the company, segment and market as a whole
CNTA - Market capitalization of the company Centessa Pharmaceuticals
The Centessa Pharmaceuticals valuation chart reflects its unique, asset-focused drug development model. The company's market capitalization depends on the success of individual programs in its portfolio. The dynamics clearly demonstrate how the market reacts to progress in clinical trials, weighing the risks and potential of each research project.
CNTA - Share of the company's market capitalization Centessa Pharmaceuticals within the market segment - Pharma neurology
Centessa Pharmaceuticals uses an innovative model to develop breakthrough drugs through a portfolio of subsidiaries. Its share of the biotech sector's market capitalization reflects the combined potential of its diverse research programs. The chart shows how investors view its unique approach to R&D and the prospects of individual drug candidates.
Market capitalization of the market segment - Pharma neurology
Here's a chart of the total market capitalization of biotech companies developing neuroscience drugs. Centessa Pharmaceuticals, with its unique asset-centric model, is an innovator. The chart demonstrates the volatility and scale of a sector with high risks but also enormous potential rewards.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart reflects investor confidence in a new, more efficient approach to drug development. Centessa Pharmaceuticals' market cap reflects its innovative model aimed at accelerating clinical trials. The line shows how its bold scientific strategy is attempting to capture market share in the global pharmaceutical industry.
Book value capitalization of the company, segment and market as a whole
CNTA - Book value capitalization of the company Centessa Pharmaceuticals
Centessa Pharmaceuticals' book value is its scientific capital. The chart below reflects the value of its pipeline, patents, and laboratory equipment. Growth in the pipeline signals success in clinical trials and progress in developing new drugs, which are the primary tangible expressions of a biotech company's value.
CNTA - Share of the company's book capitalization Centessa Pharmaceuticals within the market segment - Pharma neurology
For research-stage biopharmaceutical company Centessa, its tangible assets are cutting-edge laboratories and scientific equipment. The chart shows its share of the sector's physical infrastructure, which, although small, represents a springboard for potential scientific breakthroughs in neuroscience.
Market segment balance sheet capitalization - Pharma neurology
Centessa Pharmaceuticals uses an innovative "lightweight" model. The company manages a portfolio of biotech assets, focusing on R&D and outsourcing many functions. Its value lies in science, not buildings. The graph will show whether this capital efficiency is the new standard for the entire pharmaceutical industry.
Book value of all companies included in the broad market index - GURU.Markets
Centessa Pharmaceuticals' balance sheet represents capital strategically distributed across a portfolio of subsidiaries, each focused on developing a single breakthrough drug. The book value chart demonstrates the scale of this innovative approach to risk management in biotechnology.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Centessa Pharmaceuticals
Centessa Pharmaceuticals is a biotech company with a unique asset-centric model. Its book value is the cash allocated to its subsidiary R&D projects. Its market capitalization is the combined investor assessment of the likelihood of success for each of these projects. The chart shows how the market values this diversified portfolio of biotech bets.
Market to book capitalization ratio in a market segment - Pharma neurology
Centessa Pharmaceuticals is a biotech company with an innovative approach to drug development. Its value lies in its unique R&D model and pipeline of potential drugs, not in its physical assets. This chart shows the premium the market is willing to pay for its scientific potential compared to its book value.
Market to book capitalization ratio for the market as a whole
Centessa Pharmaceuticals is a biotech company with a unique model, managing a portfolio of subsidiaries with promising developments. The chart reflects the market's confidence in its innovative approach to drug development. The company's market valuation is based not on its current assets, but on the combined potential of its diverse research pipeline, which creates a high risk premium.
Debts of the company, segment and market as a whole
CNTA - Company debts Centessa Pharmaceuticals
Centessa Pharmaceuticals takes an innovative approach to drug development, managing a portfolio of subsidiaries with promising assets. Funding multiple parallel studies requires a flexible approach to capital. This chart shows how the company raises funds to support its diverse and risky R&D projects.
Market segment debts - Pharma neurology
Centessa Pharmaceuticals is a new type of pharmaceutical company, operating using an asset-sharing model to reduce R&D risks. Despite its innovative approach, biotechnology remains capital-intensive. This chart shows common financial metrics for the pharmaceutical industry, which can be used to assess how Centessa finances its pipeline of promising developments.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Centessa Pharmaceuticals
Centessa Pharmaceuticals uses an innovative drug development model, managing a portfolio of subsidiaries with promising assets. Biotech research is extremely expensive. This chart shows how the company finances its numerous clinical trial programs using equity and debt.
Market segment debt to market segment book capitalization - Pharma neurology
Centessa Pharmaceuticals uses an innovative model for drug development, managing a portfolio of subsidiaries with promising assets. This chart compares the debt raised to fund research with the total market capitalization of the neuroscience pharmaceutical sector. It reflects how the company finances its diverse research projects.
Debt to book value of all companies in the market
Centessa Pharmaceuticals uses an innovative model for drug development. This chart compares the company's debt to the overall book value of the economy. It helps assess how this biotech company's financial needs compare to the overall market, which is the source of its research capital.
P/E of the company, segment and market as a whole
P/E - Centessa Pharmaceuticals
This metric for Centessa Pharmaceuticals, a biotech company with a unique drug development model, should be analyzed within the context of the industry. While the company may not be profitable, its value is determined by the potential of its decentralized approach to research. The chart reflects investors' confidence in the success of its scientific platform.
P/E of the market segment - Pharma neurology
This metric represents the average valuation for the biotech sector in which Centessa operates. In this industry, filled with research-stage companies, the average earnings valuation is often uninformative. However, it reflects the overall level of investor optimism regarding scientific breakthroughs and serves as a benchmark for understanding the company's value.
P/E of the market as a whole
Centessa Pharmaceuticals uses an innovative drug development model, managing a portfolio of subsidiaries, each focused on a single program. This allows for diversification of biotech risks. This risk appetite chart helps understand how investors evaluate new approaches in the pharmaceutical industry.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Centessa Pharmaceuticals
Centessa Pharmaceuticals is a biotech company operating under a unique model, managing a portfolio of subsidiaries with promising developments. This chart reflects market expectations regarding the success of the clinical programs in its portfolio. This is an assessment not of a single technology, but of the ability of the entire business model to lead to the development of commercially successful drugs.
%20P%2FE%20Centessa%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Centessa-Pharmaceuticals&v=1772696191116 "Chart of the company's future (projected) P/E Centessa Pharmaceuticals")
Future (projected) P/E of the market segment - Pharma neurology
Centessa Pharmaceuticals is a next-generation biopharmaceutical company that takes an innovative, asset-focused approach to drug development. The company is developing a portfolio of promising programs across various therapeutic areas. This chart shows overall market sentiment toward the biotech sector, helping to assess Centessa's potential relative to the industry.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-neurology&v=1772696191117 "Future (projected) P/E graph of the market segment - Pharma neurology")
Future (projected) P/E of the market as a whole
Centessa Pharmaceuticals is a biotech company with a unique model, managing a portfolio of subsidiaries, each focused on developing a single drug. This approach diversifies biotech risks. The company's valuation is based on research success, not on overall market sentiment.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772696191131 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Centessa Pharmaceuticals
Centessa Pharmaceuticals is a biopharmaceutical company with a unique approach to drug development, managing a portfolio of subsidiaries, each focused on a single asset. Financial results primarily reflect research expenditures. This chart shows how the company invests in the early-stage development of potentially breakthrough drugs.
Profit of companies in the market segment - Pharma neurology
Centessa Pharmaceuticals is a biopharmaceutical company with a unique model, managing a portfolio of subsidiaries, each focused on a single program or drug. This chart reflects the profitability of the neuroscience pharmaceutical sector. Its decentralized approach to R&D allows for risk diversification, but overall research expenditures impact the segment's overall profitability at this time.
Overall market profit
Centessa Pharmaceuticals is a biotech company that uses an innovative approach to drug development. Its value is determined by progress in clinical trials and the potential for scientific breakthroughs. Against the backdrop of the cyclical fluctuations of the general economy, as illustrated by this chart, Centessa exemplifies a business driven by science rather than macroeconomic factors.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Centessa Pharmaceuticals
Centessa Pharmaceuticals is a pharmaceutical company that uses a unique approach to drug development, managing a portfolio of subsidiaries focused on individual assets. This chart reflects analysts' expectations for future earnings, based on the likelihood of success of clinical programs in its diverse portfolio and the potential commercialization of drugs.
%20profit%20of%20the%20company%20Centessa%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Centessa-Pharmaceuticals&v=1772696191328 "Graph of future (projected) profit of the company Centessa Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Pharma neurology
Centessa Pharmaceuticals is a pharmaceutical company using a unique model to develop innovative drugs across various therapeutic areas. This chart shows profitability forecasts for the neuroscience pharmaceutical segment. It reflects the overall investment climate in biotech and expectations for clinical trials, which shape the future of these companies.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-neurology&v=1772696191348 "Graph of future (predicted) profits of companies in a market segment - Pharma neurology")
Future (predicted) profit of the market as a whole
Centessa Pharmaceuticals takes an innovative approach to drug development, managing a portfolio of subsidiaries focused on rare diseases. Success in biotech requires significant capital. The overall profit forecast reflected here impacts the investment climate. Positive market dynamics facilitate fundraising for Centessa's breakthrough research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772696191373 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Centessa Pharmaceuticals
Centessa Pharmaceuticals is a biotech company with a unique model, managing a portfolio of subsidiaries. Revenue may not be available during the development stage. P/S will become important during commercialization, reflecting how the market evaluates initial sales and confidence in the effectiveness of its decentralized R&D model.
P/S market segment - Pharma neurology
Centessa Pharmaceuticals uses an innovative drug development model, managing a portfolio of subsidiaries, each focused on a separate program. This allows for risk diversification. The chart shows how the market values this unique approach and the combined potential of their developments, expressed as a high valuation relative to current revenue.
P/S of the market as a whole
Centessa Pharmaceuticals is a biotech company with a unique model, managing a portfolio of subsidiaries, each focused on a single drug development program. Revenue is currently virtually nonexistent. This real revenue valuation chart highlights that investors value not current revenue, but the potential for scientific discovery and a diversified approach to risk.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Centessa Pharmaceuticals
Centessa Pharmaceuticals operates under a unique model, managing a portfolio of biotech subsidiaries, each focused on a single program. This graph reflects investors' aggregated expectations for future revenue from the potential success of any one of these programs, diversifying risk within a single biotech holding.
%20P%2FS%20Centessa%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Centessa-Pharmaceuticals&v=1772696191457 "The graph of the company's future (projected) P/S Centessa Pharmaceuticals")
Future (projected) P/S of the market segment - Pharma neurology
Centessa Pharmaceuticals is a pharmaceutical company with a unique model, managing a portfolio of subsidiaries, each focused on developing a single promising drug. This chart shows how the market values the combined future sales potential of its decentralized portfolio compared to other pharmaceutical companies, reflecting its belief in its innovative approach to R&D.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-neurology&v=1772696191481 "Future (projected) P/S market segment graph - Pharma neurology")
Future (projected) P/S of the market as a whole
Centessa Pharmaceuticals is a biotech company with a unique model focused on the rapid development of promising drugs. It's a risky business, where a single success can generate enormous profits. This chart reflects overall revenue forecasts, and Centessa's example illustrates how the market evaluates the potential of scientific breakthroughs and their future economic impact.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772696191519 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Centessa Pharmaceuticals
Centessa Pharmaceuticals is a clinical-stage biopharmaceutical company using an innovative model to develop drugs for various diseases. This chart shows its revenue, which at this stage is generated not from product sales but from collaborations and licensing agreements. Future growth will depend on the successful advancement of its candidates through the clinical stages.
Sales of companies in the market segment - Pharma neurology
Centessa Pharmaceuticals is a biotech company with a unique drug development model. This chart shows its revenue structure, which during the research phase is primarily generated through collaborations and licensing agreements. It allows you to assess which of its innovative programs have already begun to generate revenue.
Overall market sales
Centessa Pharmaceuticals is a biopharmaceutical company with a unique model focused on developing drugs with a high probability of success. Its value is determined by progress in clinical trials, not by the economic climate. This timeline is not a significant factor for Centessa, whose success depends solely on scientific data and regulatory decisions.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Centessa Pharmaceuticals
Centessa Pharmaceuticals is a biopharmaceutical company with a unique model, developing multiple drugs through its subsidiaries. Its revenue forecast is highly dependent on clinical trial success. This chart reflects analysts' speculative expectations for breakthroughs in its broad and diverse pipeline.
%20sales%20of%20the%20company%20Centessa%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Centessa-Pharmaceuticals&v=1772696191570 "Schedule of future (projected) sales of the company Centessa Pharmaceuticals")
Future (projected) sales of companies in the market segment - Pharma neurology
Centessa Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs for a variety of diseases. This chart shows projected revenue for the neuroscience pharmaceutical segment. It allows investors to assess whether analysts see growth potential in this complex area, which is critical for assessing the future prospects of Centessa's pipeline.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-neurology&v=1772696191574 "Schedule of future (projected) sales of companies in the market segment - Pharma neurology")
Future (projected) sales of the market as a whole
Centessa Pharmaceuticals is a biotech company operating under a unique model, developing a portfolio of promising drugs. Its success depends on clinical trial results and its ability to raise capital. This market sentiment chart reflects investor sentiment. A positive environment facilitates the financing of risky biotech projects, which is critical for Centessa.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772696191584 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Centessa Pharmaceuticals
Centessa Pharmaceuticals is a biopharmaceutical company with an innovative drug development model. This chart illustrates the financial side of research. It shows how the company manages investments in promising programs, striving to minimize costs until it obtains compelling data that will determine its future profitability.
Market segment marginality - Pharma neurology
Centessa Pharmaceuticals uses an innovative drug development model, managing a portfolio of subsidiaries with a focus on specific drugs. This graph illustrates the potential commercial return from its unique approach. Future high profitability will demonstrate the success of its R&D strategy and the relevance of its developments.
Market marginality as a whole
Centessa Pharmaceuticals uses an innovative drug development model, managing a portfolio of subsidiaries with a high degree of autonomy. This approach focuses on several promising programs simultaneously. This graph shows average profitability, while biotechs live in a world of binary outcomes: trial failure or the creation of a blockbuster.
Employees in the company, segment and market as a whole
Number of employees in the company Centessa Pharmaceuticals
Centessa Pharmaceuticals uses an innovative model, managing a portfolio of subsidiaries, each focused on a single drug. The growth of the holding's total headcount reflects the progress of its subsidiaries' clinical programs and serves as an aggregate indicator of the development of the entire asset portfolio.
Share of the company's employees Centessa Pharmaceuticals within the market segment - Pharma neurology
Centessa Pharmaceuticals is a pharmaceutical company with a unique model, managing a portfolio of subsidiaries, each focused on a single drug development program. This chart reflects its innovative approach through its team structure. It shows how the company concentrates small but highly effective teams of scientists to accelerate scientific discovery.
Number of employees in the market segment - Pharma neurology
Centessa Pharmaceuticals is a clinical-stage biopharmaceutical company using an innovative approach to drug development. This chart illustrates the talent pool in neuroscience pharmaceuticals. The growing number of scientists in this field indicates an influx of investment in complex research, creating a favorable environment for Centessa's unique, asset-focused model.
Number of employees in the market as a whole
Centessa Pharmaceuticals is a biopharmaceutical company with an innovative drug development model. The growth of its scientific team demonstrates active research and development across a pipeline of promising drugs. This is an example of how investments in biotechnology create high-skill jobs, advancing medical science.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Centessa Pharmaceuticals (CNTA)
Centessa Pharmaceuticals is a biotech company with a unique model, managing a portfolio of R&D programs. Their value lies in their scientific potential and intellectual property. This chart shows that the market highly values their approach. The billion-dollar market capitalization, generated by a small core team and scientists, is a bet on future medical breakthroughs.
%20of%20the%20company%20Centessa%20Pharmaceuticals%20(CNTA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Centessa-Pharmaceuticals-CNTA&v=1772696191696 "Chart of market capitalization per employee (in thousands of dollars) of the company Centessa Pharmaceuticals (CNTA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma neurology
Centessa Pharmaceuticals is a clinical-stage biotech company originally created as a holding company for several R&D projects. Its value is entirely dependent on the success of these scientific programs. This chart shows the industry average, helping to assess the market value investors attribute to the potential of this R&D team.
%20by%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-neurology&v=1772696191702 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma neurology")
Market capitalization per employee (in thousands of dollars) for the overall market
Centessa Pharmaceuticals is a biotech company with a unique model, managing a portfolio of subsidiaries, each focused on a single drug development program. This chart reflects how the market values this innovative structure, where small, focused teams of scientists work on potential medical breakthroughs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772696191703 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Centessa Pharmaceuticals (CNTA)
Centessa Pharmaceuticals is a biotech company with a unique "asset-centric" model. It manages a portfolio of subsidiaries, each focused on a single R&D project. This graph, likely negative, shows how much the company invests (or loses) per employee while trying to bring several innovative drugs to market.
%20Chart%20Centessa%20Pharmaceuticals%20(CNTA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Centessa-Pharmaceuticals-CNTA&v=1772696191704 "Company Profit Per Employee (in thousands of dollars) Chart Centessa Pharmaceuticals (CNTA)")
Profit per employee (in thousands of dollars) in the market segment - Pharma neurology
Centessa Pharmaceuticals is a clinical-stage biotech company developing drugs to treat rare diseases. This chart shows the benchmark for the "Biotech" sector. In this sector, the benchmark for profit per employee is typically *deeply negative*. Companies burn through R&D (clinical trials) in anticipation of a future breakthrough.
%20in%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-neurology&v=1772696191718 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma neurology")
Profit per employee (in thousands of dollars) for the market as a whole
Centessa Pharmaceuticals is a biotech company with an asset-centric model. They manage a portfolio of subsidiaries, each focused on a single drug under R&D. This chart shows the market-average profit per employee. It helps understand how the biotech sector in which Centessa operates compares to average profitability.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772696191742 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Centessa Pharmaceuticals (CNTA)
Centessa Pharmaceuticals is a biotech company working on several drugs simultaneously. At the clinical trial stage, this graph doesn't reflect commercial viability. Rather, it illustrates the level of investment in research. If even one drug is successful, revenue per employee will skyrocket.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Centessa-Pharmaceuticals-CNTA&v=1772696191749 "Sales chart per company employee Centessa Pharmaceuticals (CNTA)")
Sales per employee in the market segment - Pharma neurology
Centessa Pharmaceuticals is a biotech company with an innovative R&D model focused on developing new drugs. Revenue is minimal during the research phase. This chart shows the average revenue per employee in this segment, serving as a productivity benchmark for commercial pharmaceutical companies and a context for assessing the effectiveness of CNTA staff.
Sales per employee for the market as a whole
Centessa Pharmaceuticals is a biotech company with an innovative model, managing a portfolio of R&D projects. As with other biotechs (CRNX, SRRK), this metric is irrelevant in the early stages. It reflects only the cost of scientists. Its dynamics will only become significant once one of their "shots" hits the target and the drug reaches the market.
Short shares by company, segment and market as a whole
Shares shorted by company Centessa Pharmaceuticals (CNTA)
Centessa Pharmaceuticals is a biotech company operating under a unique "asset-centric" model, managing a portfolio of subsidiaries with different drugs. This chart shows the odds against their approach. Bears believe this complex structure is ineffective or that their key drugs (for example, in neurology) will fail in clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Centessa-Pharmaceuticals-CNTA&v=1772696191817 "Short Shares Chart for the Company Centessa Pharmaceuticals (CNTA)")
Shares shorted by market segment - Pharma neurology
Centessa Pharmaceuticals is a biotech company with a unique model, managing a portfolio of subsidiaries, each focused on a single drug. This chart shows the overall sentiment in the biotech sector. The rise in short positions across the industry indicates that investors are generally risk-averse, preferring to exit companies dependent on successful clinical trials.
Shares shorted by the overall market
Centessa Pharmaceuticals (CNTA) is a clinical-stage biotech company using an innovative approach to drug development. They have unstable revenue. This chart measures overall market pessimism. When investors are fearful (the indicator rises), they sell off speculative biotechs that are burning cash and need external financing, regardless of CNTA's scientific potential.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Centessa Pharmaceuticals (CNTA)
Centessa Pharmaceuticals is a clinical-stage biotech. Its shares are highly sensitive to trial news. This chart for CNTA can surge above 70 on positive R&D data. Oversold territory (<30) often reflects research setbacks or general investor risk aversion in biotech.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Centessa-Pharmaceuticals-CNTA&v=1772696191881 "RSI 14 indicator chart for the company's stock Centessa Pharmaceuticals (CNTA)")
RSI 14 Market Segment - Pharma neurology
Centessa Pharmaceuticals is a biotech company with an asset-focused approach. They create subsidiaries to develop individual promising drugs, including in neuroscience. This chart measures the overall momentum of the neuroscience biotech sector. It helps determine whether the entire segment is overheated by speculative expectations.
RSI 14 for the overall market
Centessa Pharmaceuticals (CNTA) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CNTA (Centessa Pharmaceuticals)
Centessa Pharmaceuticals is a biotech company operating under a unique asset-centric model, managing a portfolio of subsidiaries with promising drugs. This chart shows the average analyst forecast. Their assessment is based on the combined risks and potential of each individual asset (drug) in the portfolio, making the analysis complex yet diversified.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CNTA-Centessa-Pharmaceuticals&v=1772696191907 "A chart showing analyst consensus forecasts for the expected stock price. CNTA (Centessa Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price CNTA (Centessa Pharmaceuticals)
Centessa Pharmaceuticals is a biopharmaceutical company with a unique model. They manage a portfolio of subsidiaries, each focused on a single promising but risky R&D project. This chart represents aggregate analyst expectations for their diverse but early pipeline of drugs. It reflects the gap between the target price and the current price.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CNTA-Centessa-Pharmaceuticals&v=1772696191927 "A chart showing the difference between the consensus forecast and the actual stock price. CNTA (Centessa Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Pharma neurology
Centessa is an "unusual" biotech. The company operates as a "holding company" with a portfolio of several R&D programs, attempting to diversify the risk of a single drug failing. This chart shows analysts' general expectations for the entire pharmaceutical sector. It reflects whether experts believe in the success of the industry's R&D pipelines.
Analysts' consensus forecast for the overall market share price
Centessa Pharmaceuticals (CNTA) is a biotech company with a unique model. They manage a portfolio of subsidiaries, each focused on a single promising molecule, allowing them to quickly close gaps. This chart shows the overall risk appetite, reflecting the willingness of investors to fund innovative but risky R&D models.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Centessa Pharmaceuticals
Centessa Pharmaceuticals is a biotech company with a differentiated approach. They manage a portfolio of asset-centric subsidiaries, each focusing on a single drug or program. This chart is an assessment of their portfolio R&D risk. It likely reflects the progress of their flagship programs (for example, in hemophilia) and their ability to quickly exit unsuccessful projects.
AKIMA Market Segment Index - Pharma neurology
Centessa Pharma is an innovative biotech (R&D model) that operates as a holding company for multiple independent R&D teams developing breakthrough drugs (for example, for narcolepsy). This consolidated metric evaluates R&D. The graph shows the average value for the segment. This benchmark: how does Centessa's unique decentralized R&D model differentiate it from the average pharmaceutical company?
The AKIM Index for the overall market
Centessa is a clinical-stage biotech company with a diversified development portfolio (immunology, neuroscience). It's a high-risk scientific bet. This chart, which reflects the market average, is an indicator of risk appetite. It reveals the macro backdrop, which is critical for funding companies like Centessa.
